Navigation Links
Volcano Reports 22 Percent Increase in Second Quarter Medical Segment Revenues and Earnings per share of $0.09

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today that revenues for the second quarter of 2011 increased 14 percent versus the second quarter a year ago in total, including a 22 percent increase in medical segment revenues versus the second quarter a year ago.

For the quarter ended June 30, 2011, Volcano reported revenues of $84.0 million versus revenues of $73.5 million in the second quarter a year ago. The company reported net income on a GAAP basis of $4.9 million, or $0.09 per diluted share, in the second quarter of 2011, versus net income on a GAAP basis of $5.4 million, or $0.10 per diluted share, in the second quarter of 2010.

Year-over-year the company's medical segment revenues increased 22 percent for the first quarter of 2011 and 24 percent for the first half of 2011. Industrial segment revenues in the second quarter declined 59 percent year-over-year and 44 percent in the first half of 2011 versus the first half of 2010 - due to the downturn in the telecom industry.

For the first six months of 2011, Volcano reported revenues of $165.0 million, an 18 percent increase over revenues of $140.0 million in the same period a year ago. The company reported GAAP net income of $6.0 million, or $0.11 per diluted share, in the first six months of 2011. This compares with GAAP net income of $1.4 million, or $0.03 per diluted share, in the same period in 2010.

"During the quarter, we continued to successfully drive our initiatives to achieve market share gains and increase utilization for our core FM (Functional Management) and IVUS (Intravascular Ultrasound) offerings. Year-over-year revenues from the sale of IVUS and FM disposables increased 22 percent and 54 percent, respectively," said Scott Huennekens, president and chief executive officer of Volcano.

"We experienced a solid quarter in Japan as activity in the country is beginning to return to normal levels following the tragic earthquake and tsunami in March. Our IVUS disposable revenues there increased 31 percent year-over-year and we have recently launched enhanced versions of our IVUS and FM disposables, as well as the VIBE® RX Vascular Imaging Balloon Catheter that provides precise, targeted balloon dilation using our intravascular imaging technology," Huennekens added.

"Our continued investments in product development and clinical programs are advancing our long-term growth strategy and fulfilling our goal of being the leading therapy guidance company. We are successfully expanding beyond a diagnosis-only company to becoming a platform company delivering precision guided therapy  of minimally invasive diagnosis and therapy utilizing visualization, physiology and other technologies that could double our potential addressable markets to more than $3.0 billion over the next several years," he continued.

Guidance for 2011

The company said it continues to expect that revenues for fiscal 2011 will be in the range of $342-$347 million. It expects that gross margin for the year will be 65-66 percent. This compares to prior guidance for gross margin of 64-65 percent. It now expects operating expenses to be 58-60 percent of revenues for the year. This compares to prior guidance for operating expenses of 57-59 percent of revenues. The company maintained its guidance for earnings per diluted share of $0.19-$0.21 for 2011.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (631) 291-4555, passcode 81779990, or via the company's website at Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through August 8, at (404) 537-3406, passcode 81779990, and via the company's website at

About Volcano

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, growth strategies, the impact of events in Japan, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent annual report on Form 10-K for the year ended December 31, 2010, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.VOLCANO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (Unaudited) June 30, December 31,20112010 Assets Current assets: Cash and cash equivalents

43,429 Short-term available-for-sale investments  

170,222175,283 Accounts receivable, net

61,50859,133 Inventories

47,45640,499 Prepaid expenses and other current assets

7,5126,643 Total current assets

322,131324,987 Long-term available-for-sale investments

45,07326,804 Property and equipment, net

62,90556,503 Intangible assets, net

15,99017,103 Goodwill

2,4872,487 Other non-current assets

431,566 Liabilities and Stockholders' Equity Current liabilities: Accounts payable

3,895 Accrued compensation

16,59718,241 Accrued expenses and other current liabilities

19,99821,960 Deferred revenues

5,7495,898 Current maturities of long-term debt

7256 Total current liabilities

55,92760,050 Long-term debt

93,43091,236 Deferred revenues

2,6882,466 Other

3,2783,478 Total liabilities

155,323157,230 Stockholders' equity

431,566VOLCANO CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(Unaudited)Three Months Ended
June 30,Six Months Ended
June 30,2011201020112010Revenues








140,024Cost of revenues26,76327,09354,63753,731Gross profit57,27346,359110,39486,293Operating expenses:Selling, general and administrative35,48830,08270,94863,161Research and development13,3219,59426,40919,452Amortization of intangibles8586211,7121,194In-process research and development-33-65Total operating expenses49,66740,33099,06983,872Operating income7,6066,02911,3252,421Interest income23283475168Interest expense(2,056)(11)(4,061)(18)Exchange rate (loss) (291)(423)(679)(544)Other-(9)(1)(19)Income before provision for income taxes5,4915,6697,0592,008Provision for income taxes6032531,015628Net income








1,380Net income per share:Basic
















0.03Shares used in calculating net income per share:Basic52,27250,45252,02050,099Diluted54,53653,07154,43052,876VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Three Months Ended
June 30,Percentage Change Six Months Ended
June 30,Percentage Change 201120102010 to 2011201120102010 to 2011Medical segment:Consoles:United States

$  5.7

$  7.3



$  11.6

$  11.5











24Rest of world





(21)Total Consoles

$  9.8


(9)$  19.7

$  19.4

1IVUS single-procedure disposables:United States





$  37.9

$  33.4












11Rest of world





30Total IVUS single-procedure disposables



22$  97.6

$  79.5

23FM single-procedure disposables:United States

$  8.7

$  6.0



$  16.8

$  11.3












48Rest of world





42Total FM single-procedure disposables



54$  31.3

$  21.3


$  4.9







%Sub-total medical segment





24Industrial segment

$  2.7










SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
2. Volcano Corporation Presentation at William Blair Conference to be Webcast
3. Volcano Corporation Presentation at Goldman Sachs Conference to be Webcast
4. Statement From Volcano Corporation on Latest St. Jude Lawsuit
5. Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
6. Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability
7. Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems
8. Volcano Corporation Presentation at Bank of America Merrill Lynch Conference to be Webcast
9. Volcano Corporation Presentation at JMP Securities Conference to be Webcast
10. Volcano Corporation Schedules First Quarter Conference Call, Webcast
11. Volcano Announces the Introduction of the PrimeWire PRESTIGE® Pressure Guide Wire in Japan
Post Your Comments:
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):